Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 4/20 | 0.76 |
| ▸ | HTR2A | P28223 | 10/20 | 0.59 |
| ▸ | HTR2C | P28335 | 4/20 | 0.59 |
| ▸ | HTR1D | P28221 | 3/20 | 0.59 |
| ▸ | MPO | P05164 | 2/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.59 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.59 |
| ▸ | HTR1B | P28222 | 2/20 | 0.59 |
| ▸ | HTR7 | P34969 | 2/20 | 0.59 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.59 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.59 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.59 |
| ▸ | CTSK | P43235 | 1/20 | 0.59 |
| ▸ | CYP2A13 | Q16696 | 1/20 | 0.59 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.57 |
| ▸ | TRPM8 | Q7Z2W7 | 3/20 | 0.49 |
| ▸ | HTR1A | P08908 | 3/20 | 0.49 |
| ▸ | HTR2B | P41595 | 2/20 | 0.49 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31036068 | 1.00 | HTR6 (0.76) | HTR6HTR2AHTR2CHTR1DMPO | |
| 5-Azatryptamine SCHEMBL3889479 | 0.86 | HTR6 (1.00) | HTR6HTR2AHTR2CHTR1DMPO | |
| 5-Azatryptamine SCHEMBL20242727 | 0.85 | HTR6 (0.97) | HTR6HTR2AHTR2CHTR1DMPO | |
| SCHEMBL3924792 | 0.83 | GSK3B (0.53) | HTR6HTR2CCYP2D6NFATC1GSK3B | |
| SCHEMBL18858475 | 0.83 | HTR6 (0.53) | HTR6HTR2AHTR1ANFATC1GSK3B | |
| SCHEMBL25030259 | 0.79 | HTR6 (0.78) | HTR6HTR2AHTR2CHTR1DMPO | |
| SCHEMBL14021920 | 0.79 | HTR6 (0.49) | HTR6HTR2ANFATC1GSK3BDYRK1A | |
| SCHEMBL26699137 | 0.79 | GPR84 (0.52) | HTR6TRPM8NFATC1GSK3BDYRK1A | |
| SCHEMBL25029930 | 0.79 | HTR2A (0.62) | HTR6HTR2AHTR2CHTR1DMPO | |
| SCHEMBL3221770 | 0.79 | DYRK1A (0.51) | HTR6NFATC1GSK3BDYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4710923-A2 | INDOLE AHR INHIBITORS AND USES THEREOF | Ikena Oncology, Inc. (US) | 2026-03-18 | — | — | EP | disclosed |
| EP-3612030-B1 | INDOLE AHR INHIBITORS AND USES THEREOF | IKENA ONCOLOGY INC (US) | 2025-12-24 | — | — | EP | disclosed |
| US-20250122205-A1 | INDOLE AHR INHIBITORS AND USES THEREOF | PAHR THERAPEUTICS, INC. | 2025-04-17 | — | — | US | disclosed |
| US-12077542-B2 | Indole AHR inhibitors and uses thereof | Ikena Oncology, Inc. (US) | 2024-09-03 | — | — | US | disclosed |
| CN-118255830-A | S1PR2 modulators and uses thereof | 北京昌平实验室 | 2024-06-28 | — | — | CN | disclosed |
| CN-110831600-B | Indole AHR inhibitors and uses thereof | 医肯纳肿瘤学公司 | 2023-10-17 | — | — | CN | disclosed |
| US-20230028336-A1 | INDOLE AHR INHIBITORS AND USES THEREOF | PAHR THERAPEUTICS, INC. | 2023-01-26 | — | — | US | disclosed |
| US-20230028336-A1 | INDOLE AHR INHIBITORS AND USES THEREOF | PAHR THERAPEUTICS, INC. | 2023-01-26 | — | — | US | disclosed |
| US-11358969-B2 | Indole AHR inhibitors and uses thereof | Ikena Oncology, Inc. (US) | 2022-06-14 | — | — | US | disclosed |
| US-11358969-B2 | Indole AHR inhibitors and uses thereof | Ikena Oncology, Inc. (US) | 2022-06-14 | — | — | US | disclosed |
| US-20080114023-A1 | AZAINDOLYLALKYLAMINE DERIVATIVES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS | WYETH (US) | 2008-05-15 | — | — | US | disclosed |
| US-20080114023-A1 | AZAINDOLYLALKYLAMINE DERIVATIVES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS | WYETH (US) | 2008-05-15 | — | — | US | disclosed |
| US-7297705-B2 | Azaindolylalkylamine derivatives as 5-hydroxytryptamine-6 ligands | WYETH (US) | 2007-11-20 | — | — | US | disclosed |
| US-7297705-B2 | Azaindolylalkylamine derivatives as 5-hydroxytryptamine-6 ligands | WYETH (US) | 2007-11-20 | — | — | US | disclosed |
| US-7297705-B2 | Azaindolylalkylamine derivatives as 5-hydroxytryptamine-6 ligands | WYETH (US) | 2007-11-20 | — | — | US | disclosed |
| US-20050020598-A1 | Azaindolylalkylamine derivatives as 5-hydroxytryptamine-6 ligands | WYETH (US) | 2005-01-27 | — | — | US | disclosed |
| US-6800640-B2 | ANTISEROTONINE AGENTS; CENTRAL NERVOUS SYSTEM DISORDERS | WYETH | 2004-10-05 | — | — | US | disclosed |
| EP-1456206-A1 | AZAINDOLYLALKYLAMINE DERIVATIVES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS | Wyeth (US) | 2004-09-15 | — | — | EP | disclosed |
| US-20030171395-A1 | Azaindolylalkylamine derivatives as 5-hydroxytryptamine-6 ligands | WYETH | 2003-09-11 | — | — | US | disclosed |
| WO-2003053970-A1 | AZAINDOLYLALKYLAMINE DERIVATIVES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS | WYETH (US) | 2003-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11358969-B2 | Indole AHR inhibitors and uses thereof | AHR, ARNT, IDO1 | HTR6 39/4885HTR2A 69/4885HTR2C 74/4885 |
| US-20250122205-A1 | INDOLE AHR INHIBITORS AND USES THEREOF | AHR, ARNT, IDO1 | HTR6 39/4885HTR2A 69/4885HTR2C 74/4885 |
| US-20030171395-A1 | Azaindolylalkylamine derivatives as 5-hydroxytryptamine-6 ligands | HTR6, HTR5A, HTR1A | HTR6 1/4885HTR2A 4/4885HTR2C 9/4885 |
| US-20230028336-A1 | INDOLE AHR INHIBITORS AND USES THEREOF | AHR, ARNT, IDO1 | HTR6 39/4885HTR2A 69/4885HTR2C 74/4885 |
| US-20050020598-A1 | Azaindolylalkylamine derivatives as 5-hydroxytryptamine-6 ligands | HTR6, HTR5A, HTR7 | HTR6 1/4885HTR2A 4/4885HTR2C 8/4885 |
| US-20080114023-A1 | AZAINDOLYLALKYLAMINE DERIVATIVES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS | HTR6, HTR5A, HTR7 | HTR6 1/4885HTR2A 4/4885HTR2C 8/4885 |
| US-12077542-B2 | Indole AHR inhibitors and uses thereof | AHR, ARNT, IDO1 | HTR6 39/4885HTR2A 69/4885HTR2C 74/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.